HDGFL2 and Miyoshi myopathy: All HRP2-targeting sgRNAs were markedly increased in bortezomib-resistant cells, and the robust rank aggregation (RRA) algorithm confirmed that HRP2 was one of the most essential genes (Figure 1C), indicating that loss of HRP2 might desensitize MM cells to bortezomib treatment.